Abstract： Objective:To investigate the effect of uterine artery embolization(UAE)combined with mifepristone and misoprostol on induced labor in patients with central placenta previa.Methods:This study was a retrospective study, 90 cases of central placenta praevia pregnancies requiring induction of labor who attended our hospital from January 2018 to July 2020 were selected for the study.The age was(33.4±5.7)years old and ranged from 22 to 45 years old.All patients were stochastic divided into 45 cases in misoprostol group and routine treatment group by the stochastic number table method.Two groups of pregnant women were given bilateral UAE before induction of labor.After UAE, mifepristone tablet was given orally.The pregnant women in the routine treatment group were given ethacridine lactate injection amniotic cavity injection for induction of labor.The pregnant women in the menorrhagia group were given misoprostol for induction of labor.The results of induced labor, hysterectomy rate and ovarian function were compared between two groups.Results:The total course of labor[(7.20±2.24)h], the time of hospitalization[(5.58±1.83)d]and the time of menorrhagia[(39.83±13.15)d]in misoprostol group were shorter than those in routine treatment group[(8.81±2.36)h, (8.14±2.37)d, (47.60±13.11)d], and the amount of hemorrhage during labor and 24 hours after delivery[(99.28±31.65)ml, (86.89±22.50)ml]were less than those in routine treatment group[(433.96±116.80)ml, (208.17±53.28)ml], the difference was statistically significant( P<0.05). The hysterectomy of misoprostol group[0%(0/45)]was better than that of routine treatment group[13.3%(6/45)], the difference was statistically significant( P<0.05). Conclusions:The successful rate and safety of uterine artery embolization combined with mifepristone and misoprostol in the induction of labor in pregnant women with central placenta previa are high.Its hemostasis is rapid and effective, can effectively reduce postoperative bleeding, shorten the period of labor and hospitalization, can significantly reduce the rate of hysterectomy and the incidence of complications related to operation, and can retain the reproductive function.It has no effect on menstrual recovery and ovarian function, so it is worthy of clinical application.